HPV Vaccination Drives to Prevent Cervical Cancer in Indonesia

Indonesia is aggressively scaling up its public health infrastructure to eliminate cervical cancer by 2030, guided by an ambitious national strategy known as the 90-75-90 target. This mission aims to ensure that women across all socioeconomic backgrounds are protected from the disease, which is the most frequent type of cancer affecting females in the country.

The government’s approach is formalized through the National Cervical Cancer Elimination Plan 2023–2030. This comprehensive framework establishes a continuum of care that begins with primary prevention through HPV vaccination and extends to secondary prevention via screening and early diagnosis, the treatment of pre-cancer and invasive cancer, and palliative care for patients with advanced-stage disease.

The 90-75-90 Elimination Strategy

To achieve the 2030 elimination goal, Indonesia has adopted specific benchmarks to measure progress across vaccination and screening pillars. The 90 target refers to the goal of achieving 90% coverage of HPV vaccination among girls and women in all target groups by 2030.

The 75 target focuses on secondary prevention, aiming to reach 75% of women aged 30–69 with cervical cancer screening by 2030. To meet this objective, the government is expanding the use of high-performance HPV DNA testing, which is regarded as a globally recognized best practice for early detection.

The final 90 target relates to treatment, ensuring that the vast majority of women identified with cervical disease or cancer receive the necessary medical intervention.

Transition to Single-Dose Vaccination

A significant shift in the primary prevention strategy involved a transition in the vaccination schedule. According to commitments made to the World Health Organization (WHO), Indonesia planned to transition to a single-dose HPV vaccination schedule by the end of 2025.

To maximize reach, the government is deploying both school-based and community-based platforms. This multi-channel approach is designed to ensure that the vaccine reaches every eligible girl and woman, reducing barriers to access across the archipelago.

Regional Implementation and Local Efforts

Implementation of these national goals is manifesting in various regional initiatives across Indonesia. In Maluku, authorities are intensifying HPV vaccination efforts specifically targeting residents between the ages of 15 and 60 to prevent cervical cancer, as reported by ANTARA News.

Similar momentum is visible in other cities. In Manado, reports from rri.co.id indicate strong enthusiasm among women participating in HPV vaccination programs facilitated by the BBPOM (National Agency of Drug and Food Control). In Bogor, local government officials, including Jenal Mutaqin, have expressed appreciation for BPOM-led vaccination drives intended to reduce the incidence of cervical cancer.

Beyond general public campaigns, targeted vaccination drives are also occurring within government institutions. For example, vaccination programs have been implemented for staff within the Ministry of ATR/BPN to protect female employees from the disease.

Public Health Context and Sustainability

The urgency of these measures is underscored by the high prevalence of cervical cancer among Indonesian women. Research published in the Asian Pacific Journal of Cancer Prevention highlights that HPV-linked illnesses and cervical cancer are potentially preventable through consistent vaccination and screening programs.

To sustain these efforts, the Indonesian government is prioritizing substantial investments in the health system. The strategy emphasizes several key pillars of progress, including:

• Governance and strong local leadership.
• Financial sustainability to maintain vaccine and screening supplies.
• Social outreach to ensure high participation rates across diverse populations.
• Evidence-based programming and multi-stakeholder collaboration involving ministries, civil society, and international development partners.

By integrating these components, Indonesia seeks to build a comprehensive partnership ecosystem capable of scaling up HPV DNA testing and vaccination to meet the 2030 deadline.